HDV
MCID: HPT015
MIFTS: 52

Hepatitis D (HDV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis D

MalaCards integrated aliases for Hepatitis D:

Name: Hepatitis D 12 76 53 44 15
Delta Hepatitis 12 53
Hepatitis Delta 59 55
Hepatitis D Infection 73
Hepatitis D Virus 59
Hdv 59

Classifications:



External Ids:

Disease Ontology 12 DOID:2047
MeSH 44 D003699
Orphanet 59 ORPHA402823
ICD10 via Orphanet 34 B17.0
UMLS via Orphanet 74 C0011226
UMLS 73 C0011226

Summaries for Hepatitis D

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis delta virus, which is an incomplete virus that requires the helper function of Hepatitis B virus to replicate and only occurs among people who are infected with the Hepatitis B virus. The infection has symptom fatigue, has symptom lethargy, has symptom anorexia, has symptom nausea, has symptom jaundice, has symptom clay-colored stools, has symptom dark urine, has symptom changes in personality, has symptom disturbances in sleep, has symptom confusion, has symptom abnormal behavior, has symptom somnolence, and has symptom coma.

MalaCards based summary : Hepatitis D, also known as delta hepatitis, is related to hepatitis and hepatitis b, and has symptoms including fatigue, jaundice and anorexia. An important gene associated with Hepatitis D is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Statin Pathway - Generalized, Pharmacokinetics and Imatinib Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Peginterferon alfa-2b and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes.

Wikipedia : 76 Hepatitis D (hepatitis delta) is a disease caused by the hepatitis D virus (HDV), a small spherical... more...

Related Diseases for Hepatitis D

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis D via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.1 F2 GPT IFNA2
2 hepatitis b 30.7 F2 GPT IFNA2
3 drug-induced hepatitis 29.6 CYP2C9 CYP2D6 IFNL3
4 viral hepatitis 29.6 F2 GPT IFNA2
5 hepatitis e 29.3 F2 GPT
6 hepatitis a 29.3 F2 GPT
7 porphyria, acute hepatic 11.2
8 viral infectious disease 10.5
9 liver disease 10.1
10 hepatitis c 10.1
11 serotonin syndrome 10.1 CYP2D6 IFNA2
12 sulfonamide allergy 10.1 CYP2C9 CYP2D6
13 hepatocellular carcinoma 10.1
14 hepatitis c virus 10.1
15 multiple chemical sensitivity 10.1 CYP2C9 CYP2D6
16 cryoglobulinemia 10.0 IFNA2 IFNL3
17 hepatoportal sclerosis 10.0 F2 GPT
18 hepatic tuberculosis 10.0 F2 GPT
19 kwashiorkor 10.0 F2 GPT
20 hepatic coma 10.0 F2 GPT
21 hemangioma of liver 10.0 F2 IFNA2
22 giant hemangioma 10.0 F2 IFNA2
23 infantile liver failure syndrome 1 10.0 F2 GPT
24 nonalcoholic steatohepatitis 10.0 F2 GPT
25 hemorrhagic fever 10.0 F2 GPT
26 choledocholithiasis 10.0 F2 GPT
27 analbuminemia 10.0 F2 GPT
28 acute liver failure 10.0 F2 GPT
29 bile duct disease 9.9 F2 GPT
30 cholecystitis 9.9 F2 GPT
31 obstructive jaundice 9.9 F2 GPT
32 hepatic encephalopathy 9.9 F2 GPT
33 alcoholic hepatitis 9.9 F2 GPT
34 wilson disease 9.9 F2 GPT
35 portal hypertension 9.9 F2 GPT
36 bilirubin metabolic disorder 9.9 F2 GPT SLC35A2
37 autoimmune hepatitis 9.8 CYP2D6 F2 GPT
38 liver cirrhosis 9.8
39 porphyria 9.8
40 cholangitis 9.8 F2 GPT
41 hellp syndrome 9.7 F2 GPT
42 coproporphyria, hereditary 9.7
43 porphyria cutanea tarda 9.7
44 sjogren syndrome 9.7
45 ischemic heart disease 9.7
46 brucellosis 9.7
47 nephrotic syndrome 9.7
48 arteriosclerosis 9.7
49 acute porphyria 9.7
50 human immunodeficiency virus infectious disease 9.7

Graphical network of the top 20 diseases related to Hepatitis D:



Diseases related to Hepatitis D

Symptoms & Phenotypes for Hepatitis D

Symptoms:

12 (show all 13)
  • fatigue
  • jaundice
  • anorexia
  • coma
  • lethargy
  • confusion
  • nausea
  • somnolence
  • abnormal behavior
  • clay-colored stools
  • dark urine
  • changes in personality
  • disturbances in sleep

Drugs & Therapeutics for Hepatitis D

Drugs for Hepatitis D (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4,Phase 3 99210-65-8, 215647-85-1
2
Ribavirin Approved Phase 4,Phase 2,Phase 1 36791-04-5 37542
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 6436030 5284616
7
Everolimus Approved Phase 4 159351-69-6 6442177
8 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
10 interferons Phase 4,Phase 3,Phase 2,Phase 1
11 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antimetabolites Phase 4,Phase 2,Phase 1
14 Vaccines Phase 4
15 Liver Extracts Phase 4,Phase 2
16 Immunosuppressive Agents Phase 4
17 Antifungal Agents Phase 4
18 Anti-Bacterial Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Antitubercular Agents Phase 4
21
Ritonavir Approved, Investigational Phase 3,Phase 2,Phase 1 155213-67-5 392622
22
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
23
Lonafarnib Investigational Phase 3,Phase 2 193275-84-2 148195
24
Tenofovir Experimental, Investigational Phase 3,Phase 2 147127-20-6 464205
25 Anti-HIV Agents Phase 3,Phase 2,Phase 1
26 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
27 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Phase 1
28 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
29 Cytochrome P-450 CYP3A Inhibitors Phase 3,Phase 2,Phase 1
30
protease inhibitors Phase 3,Phase 2,Phase 1
31 Reverse Transcriptase Inhibitors Phase 3,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
34
Ezetimibe Approved Phase 2 163222-33-1 150311
35
Coal tar Approved Phase 2 8007-45-2
36
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
37 Adjuvants, Immunologic Phase 2
38 Lipid Regulating Agents Phase 2
39 Anticholesteremic Agents Phase 2
40 Hypolipidemic Agents Phase 2
41
Tipranavir Approved, Investigational Phase 1 174484-41-4 65027
42 Iron-Dextran Complex Phase 1
43 Antibodies
44 Immunoglobulins

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
2 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
3 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
4 A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) Completed NCT02732639 Phase 3 Pegylated Interferon (PEG-IFN) alfa-2a
5 A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. Completed NCT01088659 Phase 3 peginterferon alfa-2a [Pegasys];placebo;tenofovir
6 Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) Completed NCT00686790 Phase 3
7 Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Not yet recruiting NCT03719313 Phase 3 Lonafarnib;Ritonavir;PEG IFN-alfa-2a;Placebo Lonafarnib;Placebo Ritonavir
8 A Study of Lonafarnib With or Without Ritonavir in Patients With HDV Unknown status NCT02968641 Phase 2 Lonafarnib;Ritonavir
9 A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Completed NCT03546621 Phase 2 Myrcludex B;Myrcludex-B;Myrcludex-B;Tenofovir
10 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Completed NCT02511431 Phase 2 Lonafarnib;Ritonavir
11 Lonafarnib for Chronic Hepatitis D Completed NCT01495585 Phase 2 Lonafarnib
12 A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) Completed NCT02731131 Phase 2 Peginterferon alfa-2a;Ribavirin
13 Pegylated Interferon to Treat Chronic Hepatitis D Completed NCT00023322 Phase 2 Peginterferon Alpha-2a
14 HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis Completed NCT00932971 Phase 2 PEG-IFN alfa-2a, Tenofovir;PEG-IFN alfa-2a, placebo
15 REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection Completed NCT02233075 Phase 2 REP 2139-Ca + Pegasys (TM)
16 Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Completed NCT02430181 Phase 2 lonafarnib;PEG IFN-a;Ritonavir
17 Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection Completed NCT02637999 Phase 1, Phase 2 PEG IFN alfa-2a;Myrcludex B
18 Lonafarnib With Ritonavir in HDV (LOWR-2) Completed NCT02430194 Phase 2 lonafarnib;Ritonavir;PEG IFN-a
19 Titrating-Dose of Lonafarnib in Combination With Ritonavir Completed NCT02527707 Phase 2 lonafarnib;Ritonavir
20 Lamivudine for Chronic Hepatitis B Completed NCT00001457 Phase 2 Lamivudine
21 Ezetimibe for Patients With Chronic Hepatitis D Recruiting NCT03099278 Phase 2 Ezetimibe
22 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Recruiting NCT03600714 Phase 2 Peg-interferon lambda;Lonafarnib;Ritonavir
23 Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Active, not recruiting NCT03105310 Phase 2 Pegylated interferon alfa;Ezetimibe
24 A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Active, not recruiting NCT02765802 Phase 2 Lambda
25 Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV Terminated NCT02577029 Phase 2 ARC-520;Entecavir;Tenofovir disoproxil
26 Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
27 Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Terminated NCT01316185 Phase 1 EBP921
28 Mother-to-child Hepatitis D Transmission Completed NCT02044055
29 Hepatitis Delta Infections in Hemophiliacs Completed NCT00005305
30 Delta Hepatitis and Liver Disease in Hemophiliacs Completed NCT00005304
31 The Hepatitis Delta International Network Recruiting NCT02375906
32 Evaluation of Patients With Liver Disease Recruiting NCT00001971
33 A Long Term Follow-up Study of Patients From the REP 301 Protocol Active, not recruiting NCT02876419
34 Liver Fibrosis in Zambian HIV-HBV Co-infected Patients Active, not recruiting NCT02344680 Anti-HIV Agents
35 Chronic Hepatitis B Virus Infection in Zambia Active, not recruiting NCT03158818
36 Epidemiology of Hepatitis B, C and Delta in Reunion Island Not yet recruiting NCT03362866
37 An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) Terminated NCT01861444

Search NIH Clinical Center for Hepatitis D

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: hepatitis d

Genetic Tests for Hepatitis D

Anatomical Context for Hepatitis D

MalaCards organs/tissues related to Hepatitis D:

41
Liver, Skin, Testes, T Cells, B Cells, Heart, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis D:

19
Liver

Publications for Hepatitis D

Articles related to Hepatitis D:

(show top 50) (show all 558)
# Title Authors Year
1
Prevalence of Hepatitis B virus and Hepatitis D virus coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
2
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. ( 29775812 )
2018
3
Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016. ( 29851188 )
2018
4
Hepatitis D Viremia Among Injection Drug Users in San Francisco. ( 29800369 )
2018
5
Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. ( 29910856 )
2018
6
Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D? ( 29356031 )
2018
7
Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. ( 29698488 )
2018
8
Epidemiological data for hepatitis D in Africa. ( 29241610 )
2018
9
Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma. ( 29858376 )
2018
10
A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection. ( 29941366 )
2018
11
Epidemiological data for hepatitis D in Africa - Authors' reply. ( 29241612 )
2018
12
Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia. ( 29761607 )
2018
13
Epidemiological data for hepatitis D in Africa. ( 29241611 )
2018
14
Clinical and laboratory characteristics of hepatitis d in Republic of Sakha (Yakutia). ( 29602929 )
2018
15
A comprehensive bioinformatic analysis of hepatitis D virus (HDV) full-length genomes. ( 29406571 )
2018
16
Hepatitis D diagnostics:Utilization and testing in the United States. ( 29596839 )
2018
17
Hepatitis D infection in Brazil: Prevalence and geographical distribution of anti-Delta antibody. ( 29663457 )
2018
18
Hepatitis D virus replication is sensed by MDA5 and induces IFN-I^/I> responses in hepatocytes. ( 29524530 )
2018
19
Targeting Hepatitis D. ( 29471567 )
2018
20
Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus. ( 29247673 )
2018
21
Delta hepatitis in resolved hepatitis B. ( 30395014 )
2018
22
Pathogenesis of and New Therapies for Hepatitis D. ( 30342879 )
2018
23
The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis. ( 30356409 )
2018
24
Devil hepatitis D: an orphan disease or largely underdiagnosed? ( 30368454 )
2018
25
Small Hepatitis Delta Antigen Selectively Binds to Target mRNA in Hepatic Cells: A Potential Mechanism by Which Hepatitis D Virus Down-Regulates Glutathione S-Transferase P1 and Induces Liver Injury and Hepatocarcinogenesis. ( 30153423 )
2018
26
Current and Future Management of Chronic Hepatitis D. ( 30166948 )
2018
27
Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. ( 30192887 )
2018
28
Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. ( 30228220 )
2018
29
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. ( 29152762 )
2018
30
Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. ( 29425306 )
2018
31
Hepatitis D infection should be taken in mind while evaluating neonatal outcomes related to maternal hepatitis B infection. ( 28854842 )
2017
32
Nucleic acid polymers: much-needed hope for hepatitis D? ( 28964702 )
2017
33
Potential effect of lamivudine-induced S gene mutations on liver-related pathogenesis in hepatitis D virus infection. ( 28103643 )
2017
34
Prevalence and risk factors of hepatitis D virus infection in patients with chronic hepatitis B infection attending the three main tertiary hospitals in Libya. ( 29241726 )
2017
35
Investigational drugs in development for Hepatitis D. ( 28730878 )
2017
36
A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. ( 28223128 )
2017
37
Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D. ( 28043091 )
2017
38
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. ( 27803174 )
2017
39
Drug-drug interaction potential of the hepatitis B and hepatitis D virus entry inhibitor myrcludex B assessed in vitro. ( 29134945 )
2017
40
Hepatitis D virus in Africa: several unmet needs. ( 28911754 )
2017
41
Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply. ( 28043094 )
2017
42
Hepatitis D, B and C virus (HDV/HBV/HCV) coinfection as a diagnostic problem and therapeutic challenge. ( 28856286 )
2017
43
Sequencing of the Hepatitis D Virus RNA WHO International Standard. ( 28359844 )
2017
44
Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review and meta-analysis. ( 28911765 )
2017
45
Prevalence and epidemiology of hepatitis D among patients with chronic hepatitis B virus infection: a report from Northern Spain. ( 27902514 )
2017
46
Hepatitis D ( 29261923 )
2017
47
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. ( 28964701 )
2017
48
Transmission of hepatitis D virus between spouses: A longitudinal study of the first reported Canadian case. ( 28331807 )
2017
49
A novel toolbox for the in vitro assay of hepatitis D virus infection. ( 28079152 )
2017
50
Elevated serum I^2-microglobulin in individuals coinfected with hepatitis B and hepatitis D virus in a rural settings in Southwest Nigeria. ( 29221492 )
2017

Variations for Hepatitis D

Expression for Hepatitis D

Search GEO for disease gene expression data for Hepatitis D.

Pathways for Hepatitis D

Pathways related to Hepatitis D according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.37 CYP2C9 CYP2D6
2
Show member pathways
11.29 CYP2C9 CYP2D6
3
Show member pathways
11.23 CYP2C9 CYP2D6
4
Show member pathways
11.13 CYP2C9 CYP2D6
5 10.96 CYP2C9 F2
6 10.79 IFNA2 IFNL3
7
Show member pathways
10.55 CYP2C9 CYP2D6
8
Show member pathways
9.98 IFNA2 IFNL3

GO Terms for Hepatitis D

Biological processes related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.61 F2 IFNA2 IFNL3
2 xenobiotic metabolic process GO:0006805 9.46 CYP2C9 CYP2D6
3 drug metabolic process GO:0017144 9.4 CYP2C9 CYP2D6
4 exogenous drug catabolic process GO:0042738 9.37 CYP2C9 CYP2D6
5 organic acid metabolic process GO:0006082 9.32 CYP2C9 CYP2D6
6 long-chain fatty acid biosynthetic process GO:0042759 9.26 CYP2C9 CYP2D6
7 oxidative demethylation GO:0070989 9.16 CYP2C9 CYP2D6
8 drug catabolic process GO:0042737 8.96 CYP2C9 CYP2D6
9 monoterpenoid metabolic process GO:0016098 8.62 CYP2C9 CYP2D6

Molecular functions related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.32 CYP2C9 CYP2D6
2 drug binding GO:0008144 9.26 CYP2C9 CYP2D6
3 monooxygenase activity GO:0004497 9.16 CYP2C9 CYP2D6
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 8.96 CYP2C9 CYP2D6
5 steroid hydroxylase activity GO:0008395 8.62 CYP2C9 CYP2D6

Sources for Hepatitis D

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....